Next Generation Sequencing (NGS) Market to be worth $27.5 Billion by 2030
Meticulous
Research®– a leading global market research company, published a research
report titled, “Next Generation Sequencing (NGS)
Market by Offering (Kits [Library Prep, QC, DNA Extraction], System)
Type (Genome, Exome, Targeted) Application (Reproductive, Oncology,
Infectious) Technology (SBS, Nanopore, Nanoball, SMRT Seq) – Global Forecast
to 2030.”
Download
sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5040
According to
this latest publication from Meticulous Research®, the global NGS
market is expected to reach $27.5 billion by 2030 at a CAGR of 15.8% from 2023
to 2030. The growth of the NGS market is driven by rising cancer prevalence
and increasing application of NGS in cancer treatment and research, the
declining costs of genome sequencing, technological advancements in sequencing
procedures, increasing pharmaceutical R&D expenditures, the surge in
genome mapping programs, and improvements in regulatory and reimbursement
scenarios for NGS-based diagnostic tests.
However, the
high costs of NGS systems and consumables, the availability of alternative
technologies, the low chances of identifying positive, actionable mutations
for precision medicine, and ethical and legal issues related to NGS-based
diagnosis restrain the growth of this market. The increasing applications of
NGS, the rising adoption of bioinformatics and genomic data management
solutions, and government initiatives supporting large-scale genomic
sequencing projects are expected to create growth opportunities for the
players operating in the NGS market.
However, the
lack of skilled professionals and regulatory and standardization concerns in
diagnostic testing are major challenges to market growth. The increasing
demand for NGS automation, the development of portable sequencing
technologies, and increasing partnerships and collaborations among NGS
instrument manufacturers to expand and improve product offerings are prominent
trends in the next-generation sequencing market.
Key
Players
The key
players operating in the global NGS market are Illumina, Inc. (U.S.), Thermo
Fisher Scientific Inc. (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland),
PerkinElmer, Inc. (U.S.), Qiagen N.V. (Netherlands), Agilent Technologies,
Inc. (U.S.), Pacific Biosciences of California, Inc. (U.S.), Danaher
Corporation (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore
Technologies Plc. (U.K.), 10X Genomics, Inc. (U.S.), and Beijing Genomics
Institute (BGI) (China).
NGS
Market: Future Outlook:
The global
NGS market study presents historical market data in terms of values (2021 and
2022), estimated current data (2023), and forecasts it for 2030 – NGS Market
by Offering, (Consumables [Sample Preparation Consumables {DNA Extraction and
Amplification, Library Preparation & Target Enrichment, Quality Control},
Other Consumables], NGS Platforms/Instruments, Software, Services),
Sequencing Type (Targeted Genome Sequencing, Whole Genome Sequencing,
Whole Exome Sequencing, Other Sequencing Types), Technology (Sequencing by
Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing
(SMRT), Nanopore Sequencing, DNA Nanoball Sequencing), Applications (Clinical
Applications [Reproductive Health, Oncology, Infectious Diseases, Other Clinical
Applications], Research and Other Applications [Drug Discovery, Agriculture
& Animal Research, Other Research Applications), End User (Hospitals and
Diagnostic Laboratories, Pharmaceutical & Biotechnology Companies,
Academic Institutes & Research Centers, Other End Users), and Geography.
The study also evaluates industry competitors and analyzes their market share
at the global and regional levels.
Speak to
analyst: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5041
In 2023, the
consumables segment is expected to account for the largest share of the NGS
market, by offering. The recurring use of consumables, rising demand for
NGS-based diagnostic tests, increasing applications of NGS in oncology,
reproductive health diagnosis, and drug discovery is increasing the demand for
consumables.
Among
sequencing types, the targeted genome sequencing segment is expected
to account for the largest share of the NGS market in 2023. The large share of
this segment is mainly attributed to rapid and cost-effective methods,
applications in discovering somatic mutations in complex samples such as
cancerous tumors mixed with germline DNA, and a high cult of researchers for
targeted genome sequencing to study gene-drug associations are expected to
drive the targeted genome sequencing segment.
Based on
technology, the market is segmented into sequencing by synthesis, ion
semiconductor sequencing, Single-molecule Real-time Sequencing (SMRT),
nanopore sequencing, and DNA nanoball sequencing. Among these, the sequencing
by synthesis segment is expected to account for the largest share of the NGS
market in 2023. The large share of this segment is primarily attributed to the
high accuracy of this technology in DNA sequencing, its highest yield of
error-free throughput, and the increasing incorporation of this technology in
NGS products.
In 2023, the
research and other applications segment is expected to account for the largest
share of the NGS market, by application. The growing prevalence of genetic
disorders, the increasing adoption of sequencing-based tests in laboratories,
the growing demand for personalized medicines, and the increasing NGS-based
research are factors contributing to the significant market share of this
segment.
The
pharmaceutical & biotechnology companies’ end-user segment is expected to
account for the largest share of the NGS market in 2023. The large market
share of this segment is attributed to factors such as the increasing R&D
spending by pharmaceutical & biotechnology companies and the rising
incidence of chronic diseases, which drive the adoption of NGS among
pharmaceutical & biotechnology companies.
By
geography, North America is estimated to account for the largest share
of the NGS market in 2023. The growth of this market is primarily attributed
to the increasing R&D expenditure by the pharmaceutical &
biotechnology industry, the presence of leading NGS market players in the
region, favorable government initiatives for genomics research, growing
applications of NGS-based research, rising awareness of NGS-based tests,
increasing cancer prevalence and genetic diseases, and favorable reimbursement
scenario in the region.
This
research report analyzes major geographies and provides a comprehensive
analysis of North America (U.S. and Canada), Europe (Germany, U.K., France,
Italy, Spain, and the Rest of Europe), Asia-Pacific (Japan, China, India, and
Rest of Asia-Pacific), Latin America (Brazil, Mexico, and Rest of Latin
America), and the Middle East & Africa.
Quick
Buy: https://www.meticulousresearch.com/Checkout/45664714
Key
questions answered in the report-
Which are the high-growth market segments in
terms of offering, sequencing type, technology, application, end user, and
country/region?
What was the historical market for NGS across
the globe?
What are the market forecasts and estimates
for the period 2023–2030?
What are the major drivers, restraints,
challenges, opportunities, and trends in the global NGS market?
Who are the major players in the global NGS
market?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous- research
Comments
Post a Comment